Sanavia AS

We are a New York City-based biotech focused on developing effective new immunotherapies for the 80% of cancer patients today’s treatments can’t reach. Our team includes scientists trained at Memorial Sloan-Kettering Cancer Center, Rockefeller University, Weill Cornell Medicine and Columbia University. They came here because they share our firm belief that cancer patients deserve more and better options than what’s already in the market today. Using our proprietary platform, we’re combining modern immunology with cutting-edge AI to find first-in-class cancer-specific epitopes in drug-resistant tumors. And, with the help of machine learning, we’re analyzing high throughput in vitro data to pick the right antibodies with remarkable pace and precision in order to create safe, effective therapies. If you’re a patient, investor, drug developer or scientist who believes the hardest problems in oncology are the ones worth solving, we’d love to connect.

Org.nr

915948510

Bransje (NACE)

Annen undervisning ikke nevnt annet sted

Besøksadresse

Lemenvegen 1, 275.0 Oslo

Ansatte

5-9

Telefon

0

Sist oppdatert: 10.7.2026